Latest stories on TARA
Protara Therapeutics GAAP EPS of -$0.35 beats by $0.02
Seeking Alpha58 · neutralearnings
Protara Therapeutics reports Q3 EPS (35c), consensus (36c)
The Fly53 · neutralearnings
Protara Therapeutics, Inc. (TARA) files 8-K
SEC 8-K50 · neutralgeneral
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Business Insider58 · neutralearnings
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
GlobeNewswire58 · neutralearnings
Cantor Fitzgerald reiterates Protara Therapeutics stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Protara Therapeutics management to meet with Cantor
The Fly56 · neutralgeneral
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire56 · neutralgeneral
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Insider56 · neutralgeneral
Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch
TipRanks73 · bullishproduct/pr
Protara Therapeutics reports Q2 EPS (36c), consensus (31c)
The Fly48 · neutralearnings
Protara Therapeutics GAAP EPS of -$0.36 misses by $0.03
Seeking Alpha34 · bearishearnings
Protara Therapeutics, Inc. (TARA) files 8-K
SEC 8-K50 · neutralgeneral
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Business Insider55 · neutralgeneral
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Seeking Alpha67 · bullishanalyst
Protara Therapeutics Announces Key Medical Leadership Transition
TipRanks50 · neutralgeneral
Protara Therapeutics, Inc. (TARA) files 8-K
SEC 8-K50 · neutralgeneral
Protara Therapeutics Stockholders Approve Governance and Share Increases
TipRanks50 · neutralgeneral
Protara Therapeutics, Inc. (TARA) files 8-K
SEC 8-K50 · neutralgeneral